# Evaluating the Safety, Tolerability, and Pharmacokinetics of an Investigational, Injectable HIV Medicine (GSK1265744) in HIV-Uninfected Adults

> **NCT02178800** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 199 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** GSK1265744 Tablets
- **DRUG:** Injectable GSK1265744
- **DRUG:** Placebo for GSK1265744 Tablets
- **DRUG:** Injectable Placebo for GSK1265744

## Key facts

- **NCT ID:** NCT02178800
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02
- **Primary completion:** 2017-04-05
- **Final completion:** 2018-07-13
- **Target enrollment:** 199 (ACTUAL)
- **Last updated:** 2021-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02178800

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02178800, "Evaluating the Safety, Tolerability, and Pharmacokinetics of an Investigational, Injectable HIV Medicine (GSK1265744) in HIV-Uninfected Adults". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT02178800. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*